Fig. 1Haplotype characterization and frequencies of apolipoprotein A5 (APOA5) polymorphisms in pooled metabolic syndrome and control groups constructed by Haploview software.
Table 1List of five studied SNPs at the 3éUTR of APOA5 gene
SNP ID |
Nucleotide change |
miRNA |
Algorithms |
rs619054 |
C>T |
Gain |
|
hsa-mir-28-5p |
miRNASNP, PolymiRTS Database, TargetScan, Miranda, MirSNP |
hsa-mir-3139 |
miRNASNP, PolymiRTS Database, TargetScan, Miranda, MirSNP |
hsa-mir-708-5p |
MirSNP, PolymiRTS Database, TargetScan, Miranda |
Loss |
|
hsa-mir-320e |
PolymiRTS Database, MirSNP |
rs369740771 |
T>G |
|
|
rs376976905 |
G>T |
|
|
rs192708363 |
C>A |
Gain |
|
hsa-miR-24-3p |
PolymiRTS Database, TargetScan, MirSNP |
hsa-miR-2467-5p |
PolymiRTS Database, TargetScan, MirSNP |
Loss |
|
hsa-miR-3934-3p |
PolymiRTS Database |
rs34089864 |
C>T |
Gain |
|
hsa-mir-3169 |
miRNASNP, PolymiRTS Database, TargetScan , Miranda, MirSNP |
hsa-mir-4740-5p |
PolymiRTS Database, TargetScan , MirSNP |
hsa-mir-561-5 p |
PolymiRTS Database, MirSNP |
Loss |
|
hsa-mir-4511 |
PolymiRTS Database, MirSNP |
hsa-mir-498 |
TargetScan, MirSNP |
Table 2Genotype distributions and allele frequencies of miR-TS-SNPs in controls and patients with metabolic syndrome
Group |
Genotype frequency |
Allele frequency |
Total no. |
TT no. |
TC no. |
CC no. |
χ2
|
P value |
Total no. |
T, n(%) |
C, n(%) |
χ2
|
P value |
rs619054 |
|
|
|
|
|
|
|
|
|
|
|
Case |
59 |
1 |
30 |
28 |
0.51 |
0.38 |
118 |
32 (27) |
86 (73) |
0.35 |
0.28 |
Control |
63 |
1 |
28 |
34 |
|
|
126 |
30 (24) |
96 (76) |
|
|
rs34089864 |
|
|
|
|
|
|
|
|
|
|
|
Case |
59 |
0 |
4 |
55 |
0.69 |
0.20 |
118 |
4 (3) |
114 (97) |
0.66 |
0.20 |
Control |
63 |
0 |
7 |
56 |
|
|
126 |
7 (6) |
119 (94) |
|
|
Table 3Biochemical characteristics of subjects with metabolic syndrome and controls separated according to APOA5 rs619054 different genotype groups
Characteristic |
CC |
TC+TT |
t value |
P value |
Case group |
|
|
|
|
Triglyceride, mg/dL |
115.71±8.42 |
106.26±9.87 |
0.72 |
0.24 |
Total cholesterol, mg/dL |
168.68±5.89 |
157.61±5.21 |
1.41 |
0.08 |
HDL-C, mg/dL |
43.32±1.02 |
43.42±0.90 |
0.07 |
0.47 |
LDL-C, mg/dL |
91.96±3.50 |
89.68±4.30 |
0.40 |
0.34 |
Insulin, mg/dL |
22.70±2.08 |
21.81±2.11 |
0.30 |
0.38 |
Control group |
|
|
|
|
Triglyceride, mg/dL |
75.44±4.68 |
71.07±3.77 |
0.71 |
0.24 |
Total cholesterol, mg/dL |
137.59±4.56 |
145.38±6.84 |
0.97 |
0.17 |
HDL-C, mg/dL |
48.35±2.06 |
51.66±1.68 |
1.21 |
0.11 |
LDL-C, mg/dL |
76.21±2.63 |
75.97±2.89 |
0.06 |
0.47 |
Insulin, mg/dL |
8.96±0.98 |
7.11±0.63 |
1.52 |
0.06 |
Table 4Biochemical characteristics of subjects with metabolic syndrome and controls separated according to APOA5 rs34089864 different genotype groups
Characteristic |
CC |
CT |
t value |
P value |
Case group |
|
|
|
|
Triglyceride, mg/dL |
108.44±5.96 |
142.50±54.55 |
1.32 |
0.09 |
Total cholesterol, mg/dL |
162.20±4.21 |
172.00±5.58 |
0.62 |
0.27 |
HDL-C, mg/dL |
43.24±0.69 |
45.25±3.25 |
0.75 |
0.23 |
LDL-C, mg/dL |
90.25±2.96 |
97.75±5.36 |
0.67 |
0.25 |
Insulin, mg/dL |
21.63±1.49 |
30.50±7.01 |
1.53 |
0.06 |
Control group |
|
|
|
|
Triglyceride, mg/dL |
73.61±3.22 |
72.00±10.26 |
0.164 |
0.43 |
Total cholesterol, mg/dL |
140.77±4.38 |
144.43±8.84 |
0.29 |
0.39 |
HDL-C, mg/dL |
48.82±1.29 |
58.29±6.19 |
2.25 |
0.01a
|
LDL-C, mg/dL |
75.46±2.08 |
81.14±5.07 |
0.92 |
0.18 |
Insulin, mg/dL |
7.77±0.50 |
10.77±3.82 |
1.56 |
0.06 |
Table 5Logistic regression models for the association between APOA5 rs619054, rs34089864 and metabolic syndrome risk
Allele/Genotype |
Crude |
Adjusteda
|
OR (95% CI) |
P value |
OR (95% CI) |
P value |
rs619054 |
|
|
|
|
T vs. C |
1.19 (0.679–2.12) |
0.553 |
1.314 (0.694–2.487) |
0.402 |
CT+TT vs. CC |
1.14 (0.798–1.63) |
0.473 |
1.196 (0.805–1.788) |
0.376 |
rs34089864 |
|
|
|
|
C vs. T |
1.68 (0.48–5.88) |
0.42 |
2.29 (0.56–9.30) |
0.25 |
CC vs. CT |
1.71 (0.48–6.20) |
0.40 |
2.46 (0.57–10.72) |
0.23 |
Table 6
APOA5 haplotypes identified in the case and control groups and their correlation with anthropometric and biochemical parameters
Variable |
Haplotype 1 |
Haplotype 2 |
Haplotype 3 |
P value |
Case |
|
|
|
|
BMI, kg/m2
|
26.22±0.43 |
25.91±0.69 |
22.00±1.00 |
0.09 |
Triglyceride, mg/dL |
110.89±4.85 |
108.03±10.03 |
172.33±64.59 |
0.04a
|
Total cholesterol, mg/dL |
164.39±3.42 |
157.07±5.35 |
171.33±7.83 |
0.23 |
HDL-C, mg/dL |
43.27±0.57 |
43.33±0.92 |
45.00±4.58 |
0.43 |
LDL-C, mg/dL |
90.83±2.27 |
89.00±4.39 |
93.67±4.91 |
0.44 |
Insulin, mg/dL |
21.99±1.20 |
20.94±1.99 |
24.67±5.48 |
0.40 |
Control |
|
|
|
|
BMI, kg/m2
|
17.71±0.78 |
17.75±1.25 |
17.00±0.00 |
0.48 |
Triglyceride, mg/dL |
74.02±2.67 |
72.00±3.75 |
72.00±10.26 |
0.46 |
Total cholesterol, mg/dL |
139.12±3.22 |
146.5±6.70 |
144.43±8.83 |
0.26 |
HDL-C, mg/dL |
48.52±1.11 |
51.93±1.65 |
58.29±6.19 |
0.01a
|
LDL-C, mg/dL |
75.76±1.64 |
75.90±2.79 |
81.14±5.07 |
0.33 |
Insulin, mg/dL |
8.23±0.49 |
7.11±0.61 |
10.77±3.82 |
0.08 |
Table 7Haplotype analysis for metabolic syndrome risk
Haplotype |
Crude |
Adjusteda
|
OR (95% CI) |
P value |
OR (95% CI) |
P value |
H3 vs. H2 |
2.33 (0.55–9.89) |
0.25 |
3.71 (0.69–20.11) |
0.13 |
H3 vs. H1 |
1.03 (0.77–1.39) |
0.81 |
1.08 (0.78–1.50) |
0.63 |
H1 vs. H2 |
2.17 (0.54–8.69) |
0.27 |
2.86 (0.62–13.24) |
0.18 |